Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by FarmerBettyon Oct 19, 2022 1:01pm
178 Views
Post# 35034024

RE:PMN 310 Clinical Trial

RE:PMN 310 Clinical TrialYes, bball you did care before when Acumen was on Promis's corporate presentations for months. They don't look a like a fly by company had 210 million in cash at the end of June. Actual study start June 2021 first patient dose October 2021.

BBall you are saying PMN making IND application in December, 30 day approval, dosing to begin in January or Feburary? Really quite incredible for anyone to believe, have they started recruitment doubtful before approvals. Is Promis planning like retiredcop said to pay university or med students who don't have alzheimers,  to get that gathered up in less than 30 days to begin in January? You would think that there would be a screening and vetting process like all other companies for the patients trials.

However you are pointing some important information not made public, Promis has developed a proprietary blood biomarker test, and the fact they have indicated they may do another financing in the phase 1b trial. 

<< Previous
Bullboard Posts
Next >>